For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
47
views
21
references
 Top references
cited by
95
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      80
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Passive serotherapy can confer immediate protection against microbial infection, but methods to rapidly generate human neutralizing monoclonal antibodies are not yet available. We have developed an improved method for Epstein-Barr virus transformation of human B cells. We used this method to analyze the memory repertoire of a patient who recovered from severe acute respiratory syndrome coronavirus (SARS-CoV) infection and to isolate monoclonal antibodies specific for different viral proteins, including 35 antibodies with in vitro neutralizing activity ranging from 10 −8M to 10 −11M. One such antibody confers protection in vivo in a mouse model of SARS-CoV infection. These results show that it is possible to interrogate the memory repertoire of immune donors to rapidly and efficiently isolate neutralizing antibodies that have been selected in the course of natural infection.

          Supplementary information

          The online version of this article (doi:10.1038/nm1080) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found

          Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome

          Christian Drosten, Stephan Günther, Wolfgang Preiser … (2003)
          The severe acute respiratory syndrome (SARS) has recently been identified as a new clinical entity. SARS is thought to be caused by an unknown infectious agent. Clinical specimens from patients with SARS were searched for unknown viruses with the use of cell cultures and molecular techniques. A novel coronavirus was identified in patients with SARS. The virus was isolated in cell culture, and a sequence 300 nucleotides in length was obtained by a polymerase-chain-reaction (PCR)-based random-amplification procedure. Genetic characterization indicated that the virus is only distantly related to known coronaviruses (identical in 50 to 60 percent of the nucleotide sequence). On the basis of the obtained sequence, conventional and real-time PCR assays for specific and sensitive detection of the novel virus were established. Virus was detected in a variety of clinical specimens from patients with SARS but not in controls. High concentrations of viral RNA of up to 100 million molecules per milliliter were found in sputum. Viral RNA was also detected at extremely low concentrations in plasma during the acute phase and in feces during the late convalescent phase. Infected patients showed seroconversion on the Vero cells in which the virus was isolated. The novel coronavirus might have a role in causing SARS. Copyright 2003 Massachusetts Medical Society
          Article 0 comments Cited 2280 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A novel coronavirus associated with severe acute respiratory syndrome.

            Thomas G Ksiazek, Dean Erdman, Cynthia Goldsmith … (2003)
            A worldwide outbreak of severe acute respiratory syndrome (SARS) has been associated with exposures originating from a single ill health care worker from Guangdong Province, China. We conducted studies to identify the etiologic agent of this outbreak. We received clinical specimens from patients in seven countries and tested them, using virus-isolation techniques, electron-microscopical and histologic studies, and molecular and serologic assays, in an attempt to identify a wide range of potential pathogens. None of the previously described respiratory pathogens were consistently identified. However, a novel coronavirus was isolated from patients who met the case definition of SARS. Cytopathological features were noted in Vero E6 cells inoculated with a throat-swab specimen. Electron-microscopical examination revealed ultrastructural features characteristic of coronaviruses. Immunohistochemical and immunofluorescence staining revealed reactivity with group I coronavirus polyclonal antibodies. Consensus coronavirus primers designed to amplify a fragment of the polymerase gene by reverse transcription-polymerase chain reaction (RT-PCR) were used to obtain a sequence that clearly identified the isolate as a unique coronavirus only distantly related to previously sequenced coronaviruses. With specific diagnostic RT-PCR primers we identified several identical nucleotide sequences in 12 patients from several locations, a finding consistent with a point-source outbreak. Indirect fluorescence antibody tests and enzyme-linked immunosorbent assays made with the new isolate have been used to demonstrate a virus-specific serologic response. This virus may never before have circulated in the U.S. population. A novel coronavirus is associated with this outbreak, and the evidence indicates that this virus has an etiologic role in SARS. Because of the death of Dr. Carlo Urbani, we propose that our first isolate be named the Urbani strain of SARS-associated coronavirus. Copyright 2003 Massachusetts Medical Society
            Article 0 comments Cited 2120 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Characterization of a novel coronavirus associated with severe acute respiratory syndrome.

              P Rota (2003)
              In March 2003, a novel coronavirus (SARS-CoV) was discovered in association with cases of severe acute respiratory syndrome (SARS). The sequence of the complete genome of SARS-CoV was determined, and the initial characterization of the viral genome is presented in this report. The genome of SARS-CoV is 29,727 nucleotides in length and has 11 open reading frames, and its genome organization is similar to that of other coronaviruses. Phylogenetic analyses and sequence comparisons showed that SARS-CoV is not closely related to any of the previously characterized coronaviruses.
              Article 0 comments Cited 1235 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Antonio Lanzavecchia: lanzavecchia@irb.unisi.ch
                Journal
                Journal ID (nlm-ta): Nat Med
                Journal ID (iso-abbrev): Nat. Med
                Title: Nature Medicine
                Publisher: Nature Publishing Group US (New York )
                ISSN (Print): 1078-8956
                ISSN (Electronic): 1546-170X
                Publication date (Electronic): 11 July 2004
                Publication date (Print): 2004
                Volume: 10
                Issue: 8
                Pages: 871-875
                Affiliations
                [1 ]GRID grid.29078.34, ISNI 0000 0001 2203 2861, Institute for Research in Biomedicine, Via Vela 6, ; Belllinzona, CH 6500 Switzerland
                [2 ]GRID grid.14095.39, ISNI 0000 0000 9116 4836, Institut für Virologie, ; Robert-Koch-Str. 17, Marburg, D-35037 Germany
                [3 ]GRID grid.419681.3, ISNI 0000 0001 2164 9667, Laboratory of Infectious Diseases, NIAID/NIH, ; 50 South Drive, Bethesda, 20892-8007 Maryland USA
                [4 ]Chiron Vaccines, Via Fiorentina 1, Siena, I-53100 Italy
                [5 ]GRID grid.144767.7, ISNI 0000 0004 4682 2907, Istituto di Microbiologia, Ospedale Luigi Sacco, Via Grassi 74, ; Milano, I-20175 Italy
                Article
                Publisher ID: BFnm1080
                DOI: 10.1038/nm1080
                PMC ID: 7095806
                PubMed ID: 15247913
                SO-VID: 7ba98a68-888f-40b6-a538-4572589e323e
                Copyright © © Nature Publishing Group 2004
                License:

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                Date received : 9 November 2003
                Date accepted : 26 March 2004
                Categories
                Subject: Article
                Custom metadata
                issue-copyright-statement © The Author(s), under exclusive licence to Springer Nature America, Inc. 2004

                ScienceOpen disciplines: Medicine
                Data availability:
                ScienceOpen disciplines: Medicine

                Comments

                Comment on this article

                scite_

                Similar content80

                See all similar

                Cited by307

                See all cited by

                Most referenced authors1,177

                See all reference authors